Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04822467 · ClinicalTrials.gov registry record · NA
SQ53 Disinfectant Wipes for Prevention of CRBSI
A NA study of Catheter-related Bloodstream Infection, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- NA
- Development phase
- 59
- Enrollment target
- 1
- Study location
NCT04822467: Completed NA study of Catheter-related Bloodstream Infection, sponsored by The Cleveland Clinic.
NCT04822467 is a NA study of Catheter-related Bloodstream Infection that has completed, run by The Cleveland Clinic. The registered enrollment target is 59 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04822467, a NA study of Catheter-related Bloodstream Infection, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
SQ53 is a novel antimicrobial, sporicidal solution that is based on a platform of quaternary ammonium chloride compounds. It has been tested against a wide range of bacteria, viruses, spores and fungal pathogens. Extensive laboratory testing has demonstrated the effectiveness of SQ53 impregnated wipes in cleaning surfaces including catheters over a 24 hour plus time period. SQ53 also received an in vitro evaluation of the irritancy potential using a tissue engineered human skin model and was found to have no potential for skin irritation. SQ53 is available as a sterilized pack with a single wipe inside. The pack is easy to open by tearing off the top end and presenting the contents to the operator to remove under sterile conditions. The current study will be a randomized single-blinded placebo-controlled clinical trial for SQ53 wipes intended for catheter cleaning in patients receiving home parenteral nutrition.
Primary Outcome
Reduction in the number of CRBSI experienced by participants over a six month period (1000 days)
Conditions Studied
Interventions
- DEVICE SQ53 Wipe
- DEVICE Ethanol Wipe
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2021-12-10 |
| Est. Completion | 2022-12-07 |
| Phase | NA |
What the finished NCT04822467 record still lists
NCT04822467 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Catheter-related Bloodstream Infection appearing as the primary indexed condition, and to 2 interventions - of which SQ53 Wipe is the first listed.
NCT04822467 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT04822467 about?
NCT04822467 is a clinical study titled "SQ53 Disinfectant Wipes for Prevention of CRBSI". SQ53 is a novel antimicrobial, sporicidal solution that is based on a platform of quaternary ammonium chloride compounds. It has been tested against a wide range of bacteria, viruses, spores and fungal pathogens. Extensive laboratory testing has demonstrated the effectiveness of SQ53 impregnated wip...
What is the current status of trial NCT04822467?
This trial is currently completed. It is a NA study. The enrollment target is 59 participants. The study started on 2021-12-10. Estimated completion is 2022-12-07.
What conditions does trial NCT04822467 study?
This clinical trial studies the following conditions: Catheter-related Bloodstream Infection.
What interventions are being tested in trial NCT04822467?
The interventions under investigation include: SQ53 Wipe (DEVICE), Ethanol Wipe (DEVICE).
Who is sponsoring clinical trial NCT04822467?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04822467 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04822467's enrollment target sits among peer trials
59 1256th of 2000 higher than 745 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI